Alkacel 50 mg/1 ml Ampoule (Melphalan Injection)

Buy Alkacel 50 mg/1 mL Melphalan Injection Ampoule Online

Alkacel 50 mg/1 mL Melphalan Injection Ampoule

At a Glance

Generic Name: Melphalan

Brand Name: Alkacel

Strength & Pack Size: 50 mg/1 mL single-use melphalan injection ampoule

Dosage Form & Route: Cytotoxic concentrate for IV infusion after dilution, prepared in hospital

Therapeutic Class: Alkylating agent chemotherapy

Primary Indications: Multiple myeloma and selected conditioning regimens for haematopoietic stem cell transplantation, as per local label

Typical Use in Therapy: Used in specialist oncology and haematology protocols alongside other chemotherapies and supportive medicines

Prescription Status: Prescription-only cytotoxic medicine for use in hospitals or accredited infusion centres

Storage: Store in a refrigerator at 2–8 °C in the original carton; protect from light and follow cytotoxic handling procedures

Product Description

Alkacel 50 mg/1 mL is a melphalan-based injectable chemotherapy supplied as a single-use ampoule intended for dilution and intravenous infusion in controlled hospital settings. Melphalan is an alkylating agent that has played a central role in multiple myeloma treatment and in certain high-dose conditioning regimens prior to haematopoietic stem cell transplantation. Each Alkacel ampoule contains 50 mg melphalan in 1 mL, which must be diluted according to the product information and institutional protocols before being given to the patient.

Because melphalan is highly active against dividing cells and unstable in solution, Alkacel must only be prepared by trained pharmacists or chemotherapy nurses using aseptic technique in a designated preparation area. The diluted infusion is administered via a central line or peripheral vein over a defined period, with careful monitoring of vital signs and laboratory parameters. Alkacel injection is never self-administered and is not suitable for home use.

Generic Meds Mart supplies Alkacel 50 mg/1 mL ampoules in original manufacturer cartons obtained from licensed oncology distributors. Each carton and ampoule is labelled with the brand name, generic name, strength, batch number, expiry date and storage conditions so that hospital pharmacy teams can verify every unit before it enters chemotherapy preparation workflows. Parcels are shipped in plain outer packaging without visible references to myeloma, transplantation or chemotherapy, supporting patient privacy while maintaining full traceability of oncologic medicines. Our role is limited to medicine access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Alkacel melphalan injection is most commonly used in multiple myeloma. At conventional doses, melphalan may form part of systemic treatment regimens, often in combination with other chemotherapies, immunomodulatory agents or corticosteroids. At high doses, melphalan is frequently used as a conditioning agent before autologous stem cell transplantation in eligible patients, with the aim of achieving deeper remission in relapsed or newly diagnosed myeloma.

In some centres and according to local approvals, melphalan may also be used in selected other haematologic malignancies or conditioning protocols. The exact indication, dose and schedule for Alkacel are always defined by experienced haematologists or oncologists who are familiar with melphalan-containing regimens and with the supportive care required during treatment.

How Melphalan Works in Chemotherapy

Melphalan, the active ingredient in Alkacel, is a bifunctional alkylating agent related to nitrogen mustard. It acts by forming covalent bonds with DNA, leading to cross-linking of DNA strands and interference with replication and transcription. This damage is particularly harmful to rapidly dividing cells such as malignant plasma cells in multiple myeloma, which rely on continuous DNA synthesis to survive and proliferate.

By creating DNA cross-links and associated strand breaks, melphalan triggers cell-cycle arrest and programmed cell death in susceptible tumour cells. Normal tissues with high turnover, such as bone marrow and gastrointestinal mucosa, are also affected to some degree, which explains many of the treatment-limiting toxicities associated with melphalan. In the high-dose transplant setting, melphalan is used to deliver a powerful cytotoxic hit to residual myeloma cells, followed by infusion of stem cells to re-establish healthy blood formation.

Dosage & Administration

Dosing of Alkacel melphalan injection is highly individualised and must always follow an approved protocol under specialist supervision. Regimens may use body-surface-area–based dosing expressed in mg/m², fixed mg doses or high-dose schedules in the transplant setting. The same 50 mg/1 mL ampoule can therefore be used in very different ways depending on whether the goal is systemic disease control or intensive conditioning.

Alkacel ampoules are drawn up and diluted with the specified diluent by trained staff in a pharmacy clean room or chemotherapy preparation area. Because melphalan solutions are not stable for long, the prepared infusion is typically used promptly within the time limits given in the product information. Patients receive the infusion intravenously, usually over a set period, with regular monitoring of blood pressure, heart rate, temperature and other clinical parameters. Concomitant antiemetics, hydration and other supportive medicines are often used to help manage side effects. Patients should never attempt to prepare or administer melphalan themselves.

Precautions

Before starting Alkacel, your medical team will carefully review your overall health, cardiac and renal function, liver status, pulmonary history and previous exposure to chemotherapy and radiotherapy. Melphalan can cause profound bone marrow suppression, so baseline blood counts and frequent monitoring during and after treatment are essential. Existing infections must be addressed, and prophylactic antimicrobials may be recommended in high-risk regimens.

Melphalan has mutagenic and potentially carcinogenic properties, and prior or concomitant therapies may influence the long-term risk of therapy-related myeloid neoplasms. Fertility may be affected, particularly with high-dose melphalan, and fertility preservation options are often discussed before treatment where feasible. Effective contraception is usually required during and for a period after melphalan therapy; Alkacel is generally avoided during pregnancy and breastfeeding unless the potential benefit clearly outweighs the risks and this is documented by the treating team.

Melphalan Side Effects

Common side effects

Common melphalan side effects include bone marrow suppression with neutropenia, anaemia and thrombocytopenia, leading to increased susceptibility to infections, fatigue, shortness of breath and easy bruising or bleeding. Nausea, vomiting, diarrhoea, abdominal discomfort and mucositis or mouth sores may occur, especially at higher doses. Many patients experience hair thinning or hair loss, temporary changes in taste and appetite loss during treatment. Transient increases in liver enzymes or mild changes in kidney function may also be observed and are monitored through regular blood tests.

Serious side effects

Serious melphalan adverse effects require urgent medical attention and may necessitate dose reduction, treatment delay or discontinuation. These include severe infections or sepsis, marked thrombocytopenia with significant bleeding, prolonged or profound neutropenia, serious gastrointestinal toxicity, pulmonary complications and, rarely, severe hepatic or renal impairment. Over the longer term, there is a recognised risk of therapy-related myelodysplastic syndromes or acute leukaemias in some patients exposed to alkylating agents such as melphalan, particularly when combined with other intensive treatments. Any high fever, uncontrolled bleeding, chest pain, sudden shortness of breath, confusion, severe abdominal pain or other alarming symptom during or after Alkacel therapy should be reported immediately to your haematology team or emergency services.

Storage

Unopened Alkacel 50 mg/1 mL ampoules should be stored in a refrigerator at 2–8 °C in their original cartons, protected from light and moisture, and handled according to local cytotoxic medicine guidelines. Prepared melphalan infusions have limited stability and must be used or discarded within the time frame specified in the product information and institutional protocols. Patients are not expected to store or handle Alkacel ampoules or prepared infusions at home; all storage, preparation and disposal are managed by hospital or infusion centre staff using appropriate cytotoxic waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on helping patients and clinics access essential oncology medicines such as Alkacel melphalan injection in regions where local supply or cost can be challenging. We work only with licensed manufacturers and authorised distributors that follow recognised quality standards and maintain full batch and expiry traceability. By supplying Alkacel 50 mg/1 mL ampoules in sealed original cartons, we support hospital pharmacies in verifying that each unit matches the melphalan brand and strength specified in their treatment protocols.

All Alkacel orders placed through Generic Meds Mart are processed in USD via secure online checkout. Parcels are shipped in neutral outer packaging with no visible references to multiple myeloma, transplantation or chemotherapy. Where available, tracked shipping options help oncology teams plan treatment dates and transplant schedules around confirmed delivery windows, reducing the risk of delays caused by supply interruptions. Our role is to support timely and discreet access to melphalan; decisions about whether Alkacel is appropriate and how it should be used remain entirely with your specialists.

Order Now

Before you order Alkacel 50 mg/1 mL online from Generic Meds Mart, you should already have a confirmed diagnosis and a written treatment plan from your haematologist or oncologist that specifically includes melphalan, the intended dose and the number of cycles or conditioning schedule. Your treatment centre will calculate how many Alkacel ampoules are needed and will usually coordinate delivery so that pharmacy and chemotherapy units receive the medicine in advance of planned treatment dates.

You should never attempt to self-prescribe melphalan, modify the dose on your own or substitute between different melphalan products without direct guidance from your healthcare team. If you experience new or worsening symptoms such as high fever, uncontrolled bleeding, persistent vomiting, chest pain, sudden shortness of breath or marked weakness during or after melphalan-based therapy, seek urgent medical attention. Generic Meds Mart exists to support reliable, discreet supply of Alkacel melphalan injection, while the complex clinical management of your cancer remains with your specialist team.

FAQ about Alkacel (Melphalan)

Q1: What conditions is Alkacel used to treat?

Alkacel contains melphalan, an alkylating agent used mainly in multiple myeloma and certain high-dose conditioning regimens before haematopoietic stem cell transplantation. In some centres, melphalan may also be used in selected other haematologic indications according to local approvals and guidelines.

Q2: Is Alkacel given as a drip or an injection?

Alkacel 50 mg/1 mL is supplied as an injectable melphalan formulation that must be diluted and given intravenously in hospital. Depending on the protocol, it may be infused over a defined period through a central or peripheral line. It is not intended for intramuscular injection or self-administration at home.

Q3: Will I lose my hair with Alkacel?

Hair thinning or hair loss can occur with melphalan, particularly when it is used at higher doses or in combination with other chemotherapies. Not every patient loses all hair, and regrowth usually occurs after treatment finishes, although timing varies. Your oncology team can give you a more precise estimate based on your overall regimen.

Q4: How will my doctors monitor me during Alkacel treatment?

During Alkacel therapy you will have regular blood tests to monitor blood counts, kidney and liver function, as well as clinical assessments to check for infections, bleeding, gastrointestinal symptoms and other side effects. In the transplant setting, monitoring is particularly intensive, with daily reviews until blood counts recover and complications are under control.

Q5: Can Alkacel be substituted with oral melphalan tablets?

Oral melphalan and injectable melphalan have different dosing, absorption and stability characteristics. Substitution between Alkacel injection and oral melphalan tablets is not a simple milligram-for-milligram switch and must only be done by specialists using validated protocols. You should not change formulation or brand on your own; any adjustments must be made by your haematology team.